Intra Cellular Therapies | ITCI - Stock


Intra Cellular Therapies reported $26.28M in Stock for its fiscal quarter ending in December of 2024.



Stock Change Date
Acadia Pharmaceuticals USD 34.67M 5.57M Dec/2025
ALKERMES USD 196.62M 5.63M Dec/2025
BioCryst Pharmaceuticals USD 5.4M 166K Dec/2025
Biogen USD 2.17B 41.3M Dec/2025
Bristol-Myers Squibb USD 2.76B 21M Sep/2025
Cytokinetics USD 0 0 Dec/2023
Esperion Therapeutics USD 108.54M 5.93M Sep/2025
Gilead Sciences USD 1.78B 40M Sep/2025
Halozyme Therapeutics USD 176.48M 9.32M Dec/2025
J&J USD 14.19B 45M Dec/2025
Nektar Therapeutics USD 14.46M 1.78M Jun/2024
Neurocrine Biosciences USD 69M 300K Dec/2025
Novartis USD 6.42B 114M Sep/2025
RedHill Biopharma USD 3.17M 482K Jun/2025
Supernus Pharmaceuticals USD 107.1M 63.08M Sep/2025
United Therapeutics USD 183.1M 6.6M Dec/2025
Vanda Pharmaceuticals USD 1.85M 190K Dec/2025